Stock BTAI BIOXCEL THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company BioXcel Therapeutics, Inc.

Equities

BTAI

US09075P1057

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 21:00:00 28/06/2024 BST 		5-day change 1st Jan Change
1.28 USD +0.79% Intraday chart for BioXcel Therapeutics, Inc. +12.28% -56.61%
06-25 Bioxcel Therapeutics Announces Positive Topline Results from Post-Marketing Requirement Study Evaluating Prn Treatment of Igalmi? (Dexmedetomidine) Sublingual Film for Agitation Associated with Bipolar Disorders or Schizophrenia CI
05-09 BioXcel Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Business Summary

BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence to develop medicines in neuroscience. Its subsidiary, OnkosXcel Therapeutics, develops medicines in immuno-oncology. The Company’s most advanced neuroscience candidate, BXCL501, is an investigational, proprietary, orally dissolving film formulation of Dex in development for the treatment of agitation associated with psychiatric and neurological disorders. It is continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimers disease in the at-home setting and in care facilities. Its most advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.

Number of employees: 74

Sales per Business

USD in Million2022Weight2023Weight Delta
Neuroscience and Immuno-oncology Drugs
100.0 %
0 100.0 % 1 100.0 % +268.00%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
0 100.0 % 1 100.0 % +268.00%

Managers

Managers TitleAgeSince
Vimal Mehta FOU
 Founder 63 28/03/17
Richard Steinhart DFI
 Director of Finance/CFO 66 30/09/17
Frank Yocca CTO
 Chief Tech/Sci/R&D Officer 68 31/05/17
Vincent O'Neill CTO
 Chief Tech/Sci/R&D Officer 55 30/06/17
Brennan Doyle IRC
 Investor Relations Contact - -
Chetan Lathia LAW
 General Counsel - -
Matthew Wiley PRN
 Corporate Officer/Principal 52 18/01/22
Javier Rodriguez LAW
 General Counsel 52 22/02/21
Rajiv Patni
55 -

Members of the board

Members of the board TitleAgeSince
Michael Miller BRD
 Director/Board Member 67 30/06/22
Peter Mueller CHM
 Chairman 68 31/03/17
Sandeep Laumas BRD
 Director/Board Member 56 31/08/17
Vimal Mehta FOU
 Founder 63 28/03/17
Rajiv Patni
55 -
Michal Votruba BRD
 Director/Board Member 58 06/03/19
June Bray BRD
 Director/Board Member 70 28/02/21

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 37,530,821 29,361,629 ( 78.23 %) 0 78.23 %

Shareholders

NameEquities%Valuation
BioXcel Corp.
20.48 %
7,685,501 20.48 % 14 M $
Fidelity Management & Research Co. LLC
6.646 %
2,494,116 6.646 % 5 M $
BlackRock Advisors LLC
3.403 %
1,277,256 3.403 % 2 M $
Vanguard Fiduciary Trust Co.
2.929 %
1,099,375 2.929 % 2 M $
Columbia Management Investment Advisers LLC
1.543 %
579,164 1.543 % 1 M $
STATE STREET CORPORATION
1.239 %
464,908 1.239 % 841 483 $
Geode Capital Management LLC
1.220 %
457,920 1.220 % 828 835 $
Armistice Capital LLC
0.9884 %
370,973 0.9884 % 671 461 $
Beacon Pointe Advisors LLC
0.8040 %
301,735 0.8040 % 546 140 $
Peter Mueller
0.6197 %
232,597 0.6197 % 421 001 $

Company contact information

BioXcel Therapeutics, Inc.

555 Long Wharf Drive 12th floor

06511, New Haven

+475 238 6837

http://www.bioxceltherapeutics.com
address BioXcel Therapeutics, Inc.(BTAI)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Ratings for BioXcel Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
1.28 USD
Average target price
6.3 USD
Spread / Average Target
+392.19%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
BIOXCEL THERAPEUTICS, INC. Stock BioXcel Therapeutics, Inc.
-56.61% 48.04M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+15.20% 121B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+19.67% 113B
ARGENX SE Stock argenx SE
+18.95% 26.02B
BIONTECH SE Stock BioNTech SE
-23.86% 19.39B
GENMAB A/S Stock Genmab A/S
-19.03% 15.91B
BEIGENE, LTD. Stock BeiGene, Ltd.
-20.90% 15.09B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-46.14% 15.06B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+63.85% 14.93B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+4.49% 13.85B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. BTAI Stock
  4. Company BioXcel Therapeutics, Inc.